Methods of improving tolerability, pharmacodynamics, and efficacy of beta-alanine and use therefor

A composition comprising (a) an effective amount of β-alanine or a derivative of β-alanine;

• and (b) an amount of at least one agent that modulates the N-methyl D-aspartate (NMDA) pathway,
• wherein the amount of (b) is effective to reduce intolerable paraesthesia caused by (a) to a tolerable level,
• wherein the at least one agent that modulates the NMDA pathway comprises L-theanine and Zizyphus jujuba var. spinosa botanical rhizome extract or preparation,
• wherein the composition is a solid and comprises 4 to 88% w/w of (a) and from 0.0005 to 45% w/w of (b) or is a liquid and comprises from 5 to 90% w/v of (a) and from 0.005 to 60% w/v of (b), and
• wherein the derivative of beta alanine is selected from the group consisting of N-acetyl-β-alanine, fluorinated methyl β-alanine, 3-amino-3-fluoromethylpropionic acid, a β-alanine ester, a β-alanine amide, a β-alanine salt, and β-alanine nitrate.

A composition comprising (a) an effective amount of β-alanine or a derivative of β-alanine;

• and (b) an amount of at least one agent that modulates the N-methyl D-aspartate (NMDA) pathway,
• wherein the amount of (b) is effective to reduce intolerable paraesthesia caused by (a) to a tolerable level,
• wherein the at least one agent that modulates the NMDA pathway comprises L-theanine, Celastrus paniculatus botanical rhizome preparation or extract, and Zizyphus jujuba var. spinosa botanical rhizome preparation or extract, wherein the composition is a solid and comprises 4 to 88% w/w of (a) and from 0.0005 to 45% w/w of (b) or is a liquid and comprises from 5 to 90% w/v of (a) and from 0.005 to 60% w/v of (b), and
• wherein the derivative of beta alanine is selected from the group consisting of N-acetyl-β-alanine, fluorinated methyl β-alanine, 3-amino-3-fluoromethylpropionic acid, a β-alanine ester, a β-alanine amide, a β-alanine salt, and β-alanine nitrate.